## HDAC6-IN-11

Cat. No.:HY-150694CAS No.:2409072-27-9Molecular Formula: $C_{19}H_{16}N_2O_4$ Molecular Weight:336.34Target:HDACPathway:Cell Cycle/DNA Damage; EpigeneticsStorage:Please store the product under the recommended conditions in the Certificate of Analysis.	O C C C C C C C C C C C C C C C C C C C
---	---

BIOLOGICAL ACTIVITY			
Description	HDAC6-IN-11 (Compound 9) is a selective HDAC6 inhibitor with the IC <sub>50</sub> value of 20.7 nM. HDAC6-IN-11 has more than 300-fold selectivity over HDAC other isoforms. HDAC6-IN-11 shows anti-proliferative activities against cancer cells <sup>[1]</sup> .		
IC₅₀ & Target	HDAC6 20.7 nM (IC <sub>50</sub> )	HDAC8 7750 nM (IC <sub>50</sub> )	
In Vitro	HDAC6-IN-11 (0.44-6.68 μM, 48 h) treatment shows anti-proliferative activities against A549 and HCT116 cells <sup>[1]</sup> . HDAC6-IN-11 (0-20 μM, 48 h) treatment can increase the acetylation status of H3 and tubulin <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay <sup>[1]</sup>		
	Cell Line:	A549 and HCT116 cells	
	Concentration:	0.44-6.68 μM	
	Incubation Time:	48 hours	
	Result:	Showed anti-proliferative activities to A549 and HCT116 cells (GI_{50}=3.2 and 1.82 $\mu\text{M}$ , respectively).	
	Western Blot Analysis <sup>[1]</sup>		
	Cell Line:	HCT116 cells	
	Concentration:	0, 0.6, 1.25, 2.5, 5, 10 and 20 $\mu M$	
	Incubation Time:	48 hours	

and upregulated acetylated tubulin.

Led to the increase of acetylation status of H3 and tubulin in a dose-dependent manner,

Result:



®

## Page 1 of 2

[1]. Shih-Wei Wang, et al. Synthesis and biological evaluation of 2-quinolineacrylamides. Bioorg Med Chem. 2020 Feb 1;28(3):115250.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA